Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

23.27 -0.31 (-1.31%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
Should you consider NASDAQ:AMPH for growth investing?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
3 Reasons Why Amphastar Is a Great Growth Stock
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great... 
Via Talk Markets
3 Stocks at the Forefront of Medical Innovation
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
Via InvestorPlace
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
Why NASDAQ:AMPH qualifies as a high growth stock.
Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). 
Via Chartmill
Exploring NASDAQ:AMPH's CANSLIM characteristics.
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
Evaluating NASDAQ:AMPH for Growth Investment Opportunities.
High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this. 
Via Chartmill
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Via ACCESSWIRE
Recap: Amphastar Pharma Q3 Earnings
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Via ACCESSWIRE
Earnings Preview For Amphastar Pharma
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
Via ACCESSWIRE
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.